Mesoblast Limited vs Cloudflare Inc — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Cloudflare Inc trades at $271.64 (market cap $96.69B). The key difference: Cloudflare Inc is far larger — about 44.6× Mesoblast Limited's market cap, and Cloudflare Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | NET | |
|---|---|---|
Market Cap | $2.17B | $96.69B |
Sector | Technology | Technology |
52-Week High | $20.96 | $281.69 |
52-Week Low | $12.88 | $160.16 |
Enterprise Value | $2.17B | $96.05B |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Cloudflare (NET) trades at $275.19, down 0.87% on the day, as the stock consolidates near recent highs. The company continues to demonstrate strong revenue growth with Q1 2026 earnings beating expectations, though it remains unprofitable with a -3.72% net margin. Technical indicators show a bullish trend with the stock trading above key support levels, while analyst sentiment remains positive with 72.5% recommending Buy. Recent product launches including Precursor behavioral defense highlight ongoing innovation in cybersecurity.
Outlook remains cautiously optimistic as Cloudflare leverages AI-driven cybersecurity demand, though profitability concerns and high valuations (P/S 41.75) present risks. The stock trades below consensus price target of $265.07, suggesting potential upside if execution continues. Key risks include intense competition and the company's ability to achieve sustainable profitability amid significant infrastructure investments.
Trailing returns across standard periods
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →